Radiopharmaceutical Market Growth and Demand

1
Radiopharmaceutical Market
Global Industry Survey, Growth, Competitive
Landscapeand Forecasts to 2023
2
Radiopharmaceutical Market Research Report -
Global Forecast till 2023
Market Highlights As the healthcare industry is
moving towards the personalized approaches, the
role of radiopharmaceutical is also increasing.
The radiopharmaceutical is acting as an
all-rounder radiopharmaceutical from diagnosis to
treatment for various chronic diseases such as
cancers and other neurological disorders, which
has provided an impetus to the market. Demand for
radiopharmaceuticals is growing due to raising
awareness about availability of radiation and
radioisotopes in medicine, particularly for
diagnosis and therapy for various chronic
conditions. In developed countries about one
person in 50 uses diagnostic nuclear medicine
every year, and the demand for therapy with
radioisotopes is about one-tenth of this.
Radiopharmaceuticals use radiation to provide
diagnostic information about the functioning of a
person's specific organs while radiotherapy can
be used to treat some medical conditions,
especially cancer, used to weaken or destroy
particular targeted cells.
Browse Report Details _at_ https//www.marketresearch
future.com/reports/radio-pharmaceutical-market-165
0
3
Radiopharmaceutical Market Research Report -
Global Forecast till 2023
Segmentation
The global radiopharmaceutical market is
segmented by type, type of test, application,
route of administration, and end user. By type,
it is segmented into diagnostic type
radiopharmaceuticals and therapeutic type
radiopharmaceuticals. Diagnostic type
radiopharmaceutical is further sub-segmented into
SPECT radiopharmaceutical and PET
radiopharmaceutical. Therapeutic type
radiopharmaceutical is further sub-segmented into
beta emitters, alpha emitters, brachytherapy.
SPECT radiopharmaceutical is further
sub-segmented into Technetium-99m, Thallium-201,
Iodine-123, and others. PET radiopharmaceutical
is further sub-segmented into F-18, Rubidium-82,
and others. By type of test, it is segmented
into myocardial perfusion scan, lung scan, bone
scan, white blood cell scan, gallium scan, renal
nuclear medicine scan, parathyroid scans,
hepatobiliary scans, cerebral perfusion scan and
others. Whereas, a bone scan is further
sub-segmented into Technetium-99m 1st,
fluoride-18 2nd, and others. Myocardial Perfusion
Scan, Type is sub-segmented into Technetium-99m,
Thallium-201, Rubidium-82, and others. The lung
scan by type is segmented into Xenon-133,
Krypton-81m, and others. And, White blood cell
Scan is sub-segmented into Indium-111 and
others. By application, it is segmented into
oncology, cardiology, neurology, urology, and
others. Oncology segment is further segmented
into following applications prostate cancer,
bone cancer, breast cancer and others. Cardiology
segment is further segmented into following
applications coronary artery disease,
cardiomyopathy and others. Neurology segment is
further segmented into following applications
such as traumatic brain injury, stroke,
Alzheimers disease and others. Urology is
sub-segmented into acute pyelonephritis,
congenital renal anomalies, and others. By Route
of Administration, it is segmented into oral,
intravenous and others. By End User, it is
segmented into hospitals, diagnostic centers,
research institutes and others. Request a Sample
Report _at_ https//www.marketresearchfuture.com/samp
le_request/8364
4
Radiopharmaceutical Market Research Report -
Global Forecast till 2023
Regional Outlook
The global radiopharmaceutical market is
segmented into four major regions including
Americas, Europe, Asia Pacific and the Middle
East Africa. Among these, Americas and Europe
will continue to present lucrative growth
opportunities for market players during the
forecast period. Currently, these two regions
collectively account for the largest share of the
market and the trend is likely to continue over
the next couple of years. Higher healthcare
spending and existence a robust healthcare system
system in these regions is reflecting favorably
on the market. In Asia Pacific, increased focus
on improving the quality of healthcare services
is auguring well for market players operating in
the region. During the review period, the market
in the region is expected to capture a strong
CAGR. Application Major Players in this
Research Some of the key players in this market
are Jubilant Life Sciences Ltd., Siemens AG, Sun
Pharmaceutical Industries Ltd., Bayer AG,
Cardinal Health Inc., Medtronic, General Electric
Company (GE Healthcare), Lantheus Medical
Imaging, Inc., Advanced Accelerator Applications
S.A., Mallinckrodt Pharmaceuticals, Nordion,
Inc., Canadian Nuclear Laboratories (CNL), Bracco
Diagnostic Inc., IBA Dosimetry GmbH, Avid
Radiopharmaceuticals and few others. Get
Discount _at_ https//www.marketresearchfuture.com/ch
eck-discount/1650
5
Radiopharmaceutical Market Research Report -
Global Forecast till 2023
About Us Market Research Future At Market
Research Future (MRFR), we enable our customers
to unravel the complexity of various industries
through our Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research
Reports (3R), Continuous-Feed Research (CFR), and
Market Research Consulting Services. MRFR team
have supreme objective to provide the optimum
quality market research and intelligence services
to our clients. Our market research studies by
products, services, technologies, applications,
end users, and market players for global,
regional, and country level market segments,
enable our clients to see more, know more, and do
more, which help to answer all their most
important questions. In order to stay updated
with technology and work process of the industry,
MRFR often plans conducts meet with the
industry experts and industrial visits for its
research analyst members. For more information
kindly visit www.marketresearchfuture.com or
contact us at info_at_marketresearchfuture.com Copyri
ght 2018 Market Research Future All Rights
Reserved. This document contains highly
confidential information and is the sole property
of Market Research Future. No part of it may be
circulated, copied, quoted, or otherwise
reproduced without the written approval of Market
Research Future.
6
(No Transcript)